KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Receivables (2016 - 2025)

Historic Receivables for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to $200000.0.

  • Nektar Therapeutics' Receivables changed N/A to $200000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $200000.0, marking a year-over-year change of. This contributed to the annual value of $1.1 million for FY2024, which is 3548.39% down from last year.
  • According to the latest figures from Q3 2025, Nektar Therapeutics' Receivables is $200000.0.
  • Nektar Therapeutics' Receivables' 5-year high stood at $30.2 million during Q1 2022, with a 5-year trough of $200000.0 in Q3 2025.
  • Over the past 5 years, Nektar Therapeutics' median Receivables value was $5.1 million (recorded in 2022), while the average stood at $11.5 million.
  • Its Receivables has fluctuated over the past 5 years, first plummeted by 9008.93% in 2023, then surged by 2076.79% in 2024.
  • Quarter analysis of 5 years shows Nektar Therapeutics' Receivables stood at $23.9 million in 2021, then crashed by 72.04% to $6.7 million in 2022, then tumbled by 74.48% to $1.7 million in 2023, then tumbled by 35.48% to $1.1 million in 2024, then plummeted by 81.82% to $200000.0 in 2025.
  • Its Receivables was $200000.0 in Q3 2025, compared to $1.1 million in Q4 2024 and $1.2 million in Q2 2024.